The American Journal of Medicine
Volume 118, Issue 3 , Pages 292-300, March 2005

Routine human immunodeficiency virus testing: An economic evaluation of current guidelines

  • Rochelle P. Walensky, MD, MPH

      Affiliations

    • Divisions of Infectious Disease and General Medicine, Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, Massachusetts
    • Division of Infectious Disease, Brigham and Women’s Hospital, Boston, Massachusetts
    • Corresponding Author InformationRequests for reprints should be addressed to Rochelle P. Walensky, MD, MPH, Division of General Medicine, Massachusetts General Hospital, 50 Staniford Street, 9th Floor, Boston, Massachusetts 02114.
  • ,
  • Milton C. Weinstein, PhD

      Affiliations

    • Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts
  • ,
  • April D. Kimmel

      Affiliations

    • Divisions of Infectious Disease and General Medicine, Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • George R. Seage III, ScD, MPH

      Affiliations

    • Department of Health Policy and Management, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts
  • ,
  • Elena Losina, PhD

      Affiliations

    • Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
  • ,
  • Paul E. Sax, MD

      Affiliations

    • Division of Infectious Disease, Brigham and Women’s Hospital, Boston, Massachusetts
  • ,
  • Hong Zhang, SM

      Affiliations

    • Divisions of Infectious Disease and General Medicine, Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Heather E. Smith

      Affiliations

    • Divisions of Infectious Disease and General Medicine, Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Kenneth A. Freedberg, MD, MSc

      Affiliations

    • Divisions of Infectious Disease and General Medicine, Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • A. David Paltiel, PhD

      Affiliations

    • Yale School of Medicine, New Haven, Connecticut.

Received 24 November 2003; accepted 11 July 2004.

Background

The Centers for Disease Control and Prevention guidelines recommend human immunodeficiency virus (HIV) counseling, testing, and referral for all patients in hospitals with an HIV prevalence of ≥1%. The 1% screening threshold has not been critically examined since HIV became effectively treatable in 1995. Our objective was to evaluate the clinical effect and cost-effectiveness of current guidelines and of alternate HIV prevalence thresholds.

Methods

We performed a cost-effectiveness analysis using a computer simulation model of HIV screening and disease as applied to inpatients in U.S. hospitals.

Results

At an undiagnosed inpatient HIV prevalence of 1% and an overall participation rate of 33%, HIV screening increased mean quality-adjusted life expectancy by 6.13 years per 1000 inpatients, with a cost-effectiveness ratio of $35 400 per quality-adjusted life-year (QALY) gained. Expansion of screening to settings with a prevalence as low as 0.1% increased the ratio to $64 500 per QALY gained. Increasing counseling and testing costs from $53 to $103 per person still yielded a cost-effectiveness ratio below $100 000 per QALY gained at a prevalence of undiagnosed infection of 0.1%.

Conclusion

Routine inpatient HIV screening programs are not only cost-effective but would likely remain so at a prevalence of undiagnosed HIV infection 10 times lower than recommended thresholds. The current HIV counseling, testing, and referral guidelines should now be implemented nationwide as a way of linking infected patients to life-sustaining care.

Key words:  HIV/AIDS , HIV EIA , Testing , Screening , Cost-effectiveness

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This research was funded by the National Institute of Allergy and Infectious Diseases (K23AI01794, K24AI062476, K25AI50436, R01AI42006, Center for AIDS Research P30AI42851), the National Institute of Mental Health (R01MH65869), the National Institute on Drug Abuse (R01DA015612), and the Centers for Disease Control and Prevention (S1396-20/21).

PII: S0002-9343(04)00746-6

doi:10.1016/j.amjmed.2004.07.055

The American Journal of Medicine
Volume 118, Issue 3 , Pages 292-300, March 2005